Skip to Content

Generic Tudorza Pressair Availability

Tudorza Pressair is a brand name of aclidinium, approved by the FDA in the following formulation(s):

TUDORZA PRESSAIR (aclidinium bromide - powder, metered;inhalation)

  • Manufacturer: ASTRAZENECA PHARMS
    Approval date: July 23, 2012
    Strength(s): 0.4MG/INH [RLD]

Has a generic version of Tudorza Pressair been approved?

No. There is currently no therapeutically equivalent version of Tudorza Pressair available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tudorza Pressair. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
    Patent 5,840,279
    Issued: November 24, 1998
    Inventor(s): Narodylo; Andre & Gottenauer; Wolfgang & Goede; Joachim & Lerk; Coenraad & De Boer; Anne H.
    Assignee(s): ASTA Medica Aktiengesellschaft
    Pharmaceutical powder cartridge for powder inhalers for receiving a medicament depot for a large number of pharmaceutical powder doses, having an integrated metering device which comprises at least one metering cavity for receiving a predetermined quantity of a pharmaceutical powder, the integrated metering device being capable of being moved at least out of a filling position into an emptying position approximately transversely with respect to the flow direction of the pharmaceutical powder, and an inhaler for powdered medicaments, in which inhaler the medicament can be received by a patient by means of an air stream and which has a receptacle for such a pharmaceutical powder cartridge.
    Patent expiration dates:
    • June 21, 2016
      ✓ 
      Drug product
  • Inhaler for powdered medicaments
    Patent 6,071,498
    Issued: June 6, 2000
    Inventor(s): Narodylo; Andre & Gottenauer; Wolfgang & Goede; Joachim & Lerk; Coenraad & De Boer; Anne H.
    Assignee(s): ASTA Medica Aktiengesellschaft
    Pharmaceutical powder cartridge for powder inhalers for receiving a medicament depot for a large number of pharmaceutical powder doses, having an integrated metering device which comprises at least one metering cavity for receiving a predetermined quantity of a pharmaceutical powder, the integrated metering device being capable of being moved at least out of a filling position into an emptying position approximately transversely with respect to the flow direction of the pharmaceutical powder, and an inhaler for powdered medicaments, in which inhaler the medicament can be received by a patient by means of an air stream and which has a receptacle for such a pharmaceutical powder cartridge.
    Patent expiration dates:
    • June 21, 2016
      ✓ 
      Drug product
  • Powder formulation disintegrating system and method for dry powder inhalers
    Patent 6,681,768
    Issued: January 27, 2004
    Inventor(s): Anne; Haaije de Boer & Henderik Willem; Frijlink & Doetie; Gjaltema & Joachim; Goede & Paul; Hagedoorn
    Assignee(s): Sofotec GmbH & Co. KG
    A disperser for dry powders which can be used with different dose systems, dose weights ranging from 2 to 25 mg and different types of powder formulation. In one embodiment, the disperser acts both as a de-agglomeration (disintegration; aerosolization) means and as an air classifier for especially adhesive mixtures. Only fine drug particles are emitted whereas the larger agglomerates and carrier crystals are retained by the disperser. Another embodiment enables time controlled release of carrier crystals in these mixtures. Yet another embodiment has optimized performance with spherical pellets, containing no carrier crystals. Other possible embodiments of the invention make it possible to control the total inhaler resistance and the powder deposition in the upper respiratory tract by means of the addition of a so-called sheath flow of clean air. Modifications also enable carrier retainment in the mouthpiece and elimination of the tangential flow component of the discharge cloud.
    Patent expiration dates:
    • August 7, 2022
      ✓ 
      Drug product
  • Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
    Patent 6,750,226
    Issued: June 15, 2004
    Inventor(s): Dolors Fernandez; Forner & Maria Prat; Quiñones & Maria Antonia; Buil Albero
    Assignee(s): Almirall-Prodesfarma, S.A.
    A compound according to formula (I) wherein: is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; which shows high affinity for muscarinic M3 receptors (Hm3).
    Patent expiration dates:
    • September 5, 2020
      ✓ 
      Patent use: TREATMENT OF A RESPIRATORY DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent 7,078,412
    Issued: July 18, 2006
    Inventor(s): Fernandez Forner; Maria Dolors & Prat Quiñones; Maria & Buil Albero; Maria Antonia
    Assignee(s): Almirall Prodesfarma AG
    The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.
    Patent expiration dates:
    • July 16, 2020
      ✓ 
      Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
    Patent 8,051,851
    Issued: November 8, 2011
    Inventor(s): Herder; Martin & Mett; Ingo & Goede; Joachim
    Assignee(s): Sofotec GmbH & Co. KG
    In order to improve the security and reliability of administration of powdered pharmaceuticals through dry powder inhalers, the invention proposes an inhaler (1) for powdered medicaments, comprising an activating device (4) for manual engagement by the patient for repeatedly metering a dose of medicament to be administered to the patient, and further comprising an advancing mechanism (25) for advancing a counter or indexing means (8) each time the activating device (4) has been engaged by the patient so that a dose of medicament has been released for administration to the patient, wherein the counter or indexing means (8) comprises an index (9), the index (9) being detectable by a detection means (10) of the inhaler, and the detection means (10) being coupled to a locking mechanism (12), the locking mechanism (12) blocking the activating device (4) and/or any transportation mechanism (5) of the inhaler (1) delayed by a predetermined number of metering cycles since detection of the index (9), and a cartridge (3).
    Patent expiration dates:
    • April 22, 2027
      ✓ 
      Drug product
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent 9,056,100
    Issued: June 16, 2015
    Assignee(s): ALMIRALL, S.A.
    Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide and methods of using the same.
    Patent expiration dates:
    • July 7, 2020
      ✓ 
      Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
      ✓ 
      Drug product
  • Quinuclidine derivatives and medicinal compositions containing the same
    Patent 9,333,195
    Issued: May 10, 2016
    Assignee(s): ALMIRALL, S.A.
    Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
    Patent expiration dates:
    • July 7, 2020
      ✓ 
      Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 23, 2017 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide